TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37069531

Group type: EXPERIMENTAL
Intervention: gCJD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy relatives (HR)
Number of subjects: 0
Study: 37069593

Group type: EXPERIMENTAL
Intervention: Clinical social worker
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Peer recovery specialist
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 37069599

Group type: EXPERIMENTAL
Intervention: Back School intervention (8-week program, 2 sessions per week, 16 sessions total, 45 min each)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Back School intervention
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no lifestyle changes)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison between EG and CG
Number of subjects: 58
Study: 37069685

Group type: EXPERIMENTAL
Intervention: Quantra QPlus System
Number of subjects: 128
Study: 37069970

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg or 15 mg (doses pooled for analyses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37070017

Group type: EXPERIMENTAL
Intervention: MARIGOLD (Mobile Affect Regulation Intervention with the Goal of Lowering Depression)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37070261

Group type: EXPERIMENTAL
Intervention: Thinking for a Change intervention
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 37070436

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (once daily for 12 weeks)
Number of subjects: 72
Study: 37070473

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (vitamin K antagonist)
Number of subjects: 0
Study: 37070491

Group type: EXPERIMENTAL
Intervention: Simulation-based teaching
Number of subjects: 324

Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 324
Study: 37070556

Group type: EXPERIMENTAL
Intervention: Long cART exposure (cART initiation preconception)
Number of subjects: 44

Group type: COMPARATOR
Intervention: HIV-unexposed-children (HUU)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Increased methionine-sulfone levels in children
Number of subjects: 44
Study: 37070653

Group type: EXPERIMENTAL
Intervention: Camizestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aromatase inhibitor + CDK4/6 inhibitor
Number of subjects: 0
Study: 37070660

Group type: COMPARATOR
Intervention: PFMT plus biofeedback
Number of subjects: 3079

Group type: COMPARATOR
Intervention: Combinations of conservative treatments
Number of subjects: 3079

Group type: COMPARATOR
Intervention: Electrical or magnetic stimulation
Number of subjects: 3079
Study: 37070673

Group type: COMPARATOR
Intervention: Living in extreme poverty (defined as below 120% of federal poverty thresholds) during ALL maintenance therapy.
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Not living in extreme poverty (above 120% of federal poverty thresholds) during ALL maintenance therapy.
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Children living in extreme poverty (nonadherence to mercaptopurine).
Number of subjects: 592

Group type: COMPARATOR
Intervention: Children not living in extreme poverty (nonadherence to mercaptopurine).
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Children living in extreme poverty (hazard of relapse).
Number of subjects: 592
Study: 37070715

Group type: EXPERIMENTAL
Intervention: Aquatic exercises + Pain Neuroscience Education (PNE)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aquatic exercises (AEG)
Number of subjects: 75
Study: 37070830

Group type: EXPERIMENTAL
Intervention: Secretory-IgA (SIgA) binding to intestinal microbiota
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SIgA affinity to the microbiota
Number of subjects: 0
Study: 37070852

Group type: EXPERIMENTAL
Intervention: Pelacarsen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olpasiran
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SLN360
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LY3819469
Number of subjects: 0
Study: 37070854

Group type: EXPERIMENTAL
Intervention: Clinical features, NCCT radiological features, and radiomic features
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: NCCT radiological features
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Clinical & radiomic combination model
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Addition of radiomics features
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: NCCT radiological signs
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Radiomic features
Number of subjects: 317
Study: 37071035

Group type: EXPERIMENTAL
Intervention: HD incorporating 30 minutes of aerobic exercise (HDEX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard HD
Number of subjects: 60
Study: 37071038

Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ustekinumab→Guselkumab
Number of subjects: 0
Study: 37071094

Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 823

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 823
Study: 37071112

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CBA)
Number of subjects: 2709
Study: 37071166

Group type: EXPERIMENTAL
Intervention: Experimental group (0.7 mL/kg iohexol 350 mgI/mL)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group (1.4 mL/kg iohexol 350 mgI/mL)
Number of subjects: 212
Study: 37071285

Group type: EXPERIMENTAL
Intervention: FMS + OSAS
Number of subjects: 69

Group type: COMPARATOR
Intervention: OSAS only
Number of subjects: 69
Study: 37071317

Group type: COMPARATOR
Intervention: Expert opinion elicitation in Bayesian analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayesian analysis using expert opinion
Number of subjects: 0
Study: 37071469

Group type: EXPERIMENTAL
Intervention: L-ficolin, hyaluronic acid (HA), and stimulation 2 (ST2) measured on day 3 after HCT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low L-ficolin levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High HA levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High ST2 levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: L-ficolin levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HA levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ST2 levels
Number of subjects: 80
Study: 37071612

Group type: EXPERIMENTAL
Intervention: eHealth Familias Unidas Mental Health intervention
Number of subjects: 468
Study: 37071764

Group type: EXPERIMENTAL
Intervention: Apalutamide combined with abiraterone and prednisone
Number of subjects: 972

Group type: COMPARATOR
Intervention: Placebo combined with abiraterone and prednisone
Number of subjects: 972
Study: 37071834

Group type: EXPERIMENTAL
Intervention: Cisplatin combination chemotherapy
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Obesity at diagnosis
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Smoking at diagnosis
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Raynaud's phenomenon
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Positive family history for CVD
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: CVD in TC survivors
Number of subjects: 4748

Group type: EXPERIMENTAL
Intervention: Clinical evaluation for cardiovascular risk factors
Number of subjects: 4748
Study: 37071836

Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab
Number of subjects: 202

Group type: COMPARATOR
Intervention: Watch and wait strategy (control)
Number of subjects: 202
Study: 37071838

Group type: EXPERIMENTAL
Intervention: Avelumab first-line maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37072105

Group type: EXPERIMENTAL
Intervention: AZD4831 5 mg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 37072143

Group type: EXPERIMENTAL
Intervention: Early reconstruction with sepsis control (Group B)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Early reconstruction without sepsis control (Group A)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Delayed reconstruction (Group C)
Number of subjects: 277
Study: 37072180

Group type: EXPERIMENTAL
Intervention: Long-POEM (13 cm)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Short-POEM (8 cm)
Number of subjects: 200
Study: 37072219

Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 1814

Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 1814

Group type: COMPARATOR
Intervention: Timed 25-foot walk (T25FW)
Number of subjects: 1814
Study: 37072346

Group type: EXPERIMENTAL
Intervention: CD45RA-depleted PBMCs (RAD-PBMCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated whole PBMCs (W-PBMCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naïve T-cell fraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: CD45RA+ regulatory T cells, natural killer cells, stem cell memory, and effector memory subsets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD45RA depletion of PBMCs from patients with lymphoma
Number of subjects: 0
Study: 37072349

Group type: EXPERIMENTAL
Intervention: Polio virotherapy with prior polio vaccination
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intratumor recall of poliovirus or tetanus immunity
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intratumor recall antigens
Number of subjects: 2
Study: 37072361

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-every-3-months (PP3M)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Risperidone (oral run-in)
Number of subjects: 33
Study: 37072364

Group type: EXPERIMENTAL
Intervention: Artificial intelligence system using physiological signals from wearable sensors (ECG and continuous glucose monitor)
Number of subjects: 30
Study: 37072421

Group type: EXPERIMENTAL
Intervention: Venetoclax plus obinutuzumab (Ven-Obi)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Chlorambucil plus obinutuzumab (Clb-Obi)
Number of subjects: 432
Study: 37072512

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37072571

Group type: EXPERIMENTAL
Intervention: Sapanisertib with carboplatin and paclitaxel
Number of subjects: 17
Study: 37072577

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glimepiride 4 mg/day
Number of subjects: 60
Study: 37072603

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with gallium-aluminum-arsenide (GaAlAs) diode laser (810 nm, continuous-wave mode, 1000 mW, 0.28 cm)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 22
Study: 37072607

Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI, 80 U, subcutaneous, twice weekly for 24 weeks)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Repository Corticotropin Injection (RCI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 37072730

Group type: EXPERIMENTAL
Intervention: Accelerated pulsed high-fluence corneal cross-linking (pl-ACXL, 30 mW/cm²)
Number of subjects: 27
Study: 37072737

Group type: EXPERIMENTAL
Intervention: EMI
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: EMI + Virtual Home Visiting with CHW + Video Feedback
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: EMI + Hybrid Home Visiting with CHW + Video Feedback
Number of subjects: 525
Study: 37072778

Group type: EXPERIMENTAL
Intervention: Feverkidstool
Number of subjects: 8211

Group type: EXPERIMENTAL
Intervention: Craig model
Number of subjects: 8211

Group type: EXPERIMENTAL
Intervention: SBI score
Number of subjects: 8211

Group type: EXPERIMENTAL
Intervention: PAWS
Number of subjects: 8211
Study: 37072812

Group type: EXPERIMENTAL
Intervention: 15-week specialized low-intensity rehabilitation program, including exercise and respiratory therapy and mental gait training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 90
Study: 37072843

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nystatin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: C. albicans
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Non-C. albicans species
Number of subjects: 45
Study: 37073174

Group type: EXPERIMENTAL
Intervention: Training adaptation intervention, details not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group advised to reduce intensity and amount of training, details not specified.
Number of subjects: 0
Study: 37073421

Group type: EXPERIMENTAL
Intervention: Aspirin (prophylactic, dosage not specified)
Number of subjects: 2296
Study: 37073442

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine and bupivacaine (100 μg morphine and 15 mg bupivacaine)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (nonspinal group)
Number of subjects: 96
Study: 37073512

Group type: EXPERIMENTAL
Intervention: GORE VIABAHN VBX Balloon Expandable Endoprosthesis
Number of subjects: 59
Study: 37073741

Group type: EXPERIMENTAL
Intervention: Vincristine/irinotecan/temsirolimus (VIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Vincristine/irinotecan (VI) alone
Number of subjects: 36
Study: 37073753

Group type: EXPERIMENTAL
Intervention: Offline anosognosia rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard neglect rehabilitation
Number of subjects: 0
Study: 37073794

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (discontinued anti-fibrotic therapy > 5 medication half-lives)
Number of subjects: 0
Study: 37073797

Group type: EXPERIMENTAL
Intervention: Secondary hospitals
Number of subjects: 4978

Group type: COMPARATOR
Intervention: Tertiary hospitals
Number of subjects: 4978
Study: 37073882

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Number of subjects: 0
Study: 37073926

Group type: EXPERIMENTAL
Intervention: AneuFix elastomer injection into the endoleak cavity and lumbar arteries
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 10
Study: 37074202

Group type: EXPERIMENTAL
Intervention: mRNA-1283 vaccine
Number of subjects: 0
Study: 37074330

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37074522

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 60
Study: 37074571

Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD (pNET cohort)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD (epNET cohort)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Surufatinib 300 mg QD (both cohorts)
Number of subjects: 35
Study: 37074613

Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg on day 1 and 100 mg on days 2 and 3)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 37074698

Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Therapy (IPT)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 234
Study: 37074706

Group type: EXPERIMENTAL
Intervention: Laparoscopic elective sigmoid resection
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 85
Study: 37074705

Group type: EXPERIMENTAL
Intervention: Tralokinumab 150 mg
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 37074715

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 135
Study: 37074775

Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA) with digital appointment reminders
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA) with standard of care (SOC) counseling
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Digital appointment reminders
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard of care (SOC) for PrEP choice (oral or CAB-LA)
Number of subjects: 1200
Study: 37074948

Group type: EXPERIMENTAL
Intervention: Expressive Interviewing
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control Task
Number of subjects: 151
Study: 37074998

Group type: EXPERIMENTAL
Intervention: Standardized patient actor (SP) HCW training intervention
Number of subjects: 4595

Group type: EXPERIMENTAL
Intervention: Newly enrolled YLHIV
Number of subjects: 4595

Group type: EXPERIMENTAL
Intervention: Wave 3 satisfaction with care scores
Number of subjects: 4595
Study: 37075126

Group type: EXPERIMENTAL
Intervention: H1 stem immunogen (H1ssF)
Number of subjects: 0
Study: 37075127

Group type: EXPERIMENTAL
Intervention: mRNA-1273 COVID-19 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37075129

Group type: EXPERIMENTAL
Intervention: 20 μg of H1ssF once
Number of subjects: 52
Study: 37075142

Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring for the first 72 hours after birth
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1601
Study: 37075254

Group type: EXPERIMENTAL
Intervention: 177 Lu-DOTA-EB-TATE without amino acid infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: 177 Lu-DOTA-EB-TATE with amino acid infusion
Number of subjects: 10
Study: 37075255

Group type: EXPERIMENTAL
Intervention: Weekly dose-dense chemotherapy
Number of subjects: 1566

Group type: COMPARATOR
Intervention: Standard three-weekly carboplatin-paclitaxel regimens
Number of subjects: 1566
Study: 37075301

Group type: EXPERIMENTAL
Intervention: Multiprobe PET/MRI in EOAD (n=49)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multiprobe PET/MRI in EOAD (n=75)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Multiprobe PET/MRI in EOAD (n=18)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Multiprobe PET/MRI in LOAD (n=44)
Number of subjects: 133
Study: 37075495

Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section (FS) of sentinel lymph nodes (SLNs)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Para-aortic lymphadenectomy
Number of subjects: 126
Study: 37075617

Group type: EXPERIMENTAL
Intervention: Mobocertinib 160 mg QD
Number of subjects: 164

Group type: COMPARATOR
Intervention: Real-world treatments (EGFR TKI 20%, immuno-oncology therapy 40%, chemotherapy 40%)
Number of subjects: 164
Study: 37075781

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus gemcitabine and cisplatin
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and cisplatin
Number of subjects: 1069
Study: 37075847

Group type: EXPERIMENTAL
Intervention: Prenatal vitamin D supplementation (4400 IU/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (400 IU/day)
Number of subjects: 0
Study: 37075965

Group type: EXPERIMENTAL
Intervention: 8-week self-administered dyadic intervention (ReStoreD) consisting of activities completed individually and as a couple.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Care partner baseline resilience scores
Number of subjects: 34
Study: 37076108

Group type: COMPARATOR
Intervention: Endovascular repair (ER)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 789
Study: 37076132

Group type: EXPERIMENTAL
Intervention: Risk-based follow-up strategies for G-(MA)NEC
Number of subjects: 801

Group type: COMPARATOR
Intervention: Control strategy recommended by the guidelines
Number of subjects: 801
Study: 37076142

Group type: EXPERIMENTAL
Intervention: Postoperative occurrence of nosocomial infections
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Major adverse cardiac events
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Pulmonary complications
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Acute kidney injury
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Delirium/acute encephalopathy
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Long-term occurrence of psychopathology
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Chronic pain
Number of subjects: 431
Study: 37076159

Group type: EXPERIMENTAL
Intervention: Atezolizumab (TECENTRIQ, F. Hoffmann-La Roche Ltd/Genentech) with local standard-of-care support and Roche DPM Module
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible care with subcutaneous atezolizumab (1875 mg; Day 1 of each 21-day cycle) administered in the hospital, followed by 13 cycles at home by a healthcare professional
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local standard-of-care support without Roche DPM Module
Number of subjects: 0
Study: 37076197

Group type: EXPERIMENTAL
Intervention: INFO
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: INFO+DELIV
Number of subjects: 767

Group type: COMPARATOR
Intervention: Control
Number of subjects: 767
Study: 37076252

Group type: EXPERIMENTAL
Intervention: Bupivacaine implant (300 mg, three 100 mg implants)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo (three collagen implants)
Number of subjects: 365
Study: 37076424

Group type: EXPERIMENTAL
Intervention: Beta-lactam therapeutic drug monitoring (BL TDM)
Number of subjects: 138
Study: 37076476

Group type: EXPERIMENTAL
Intervention: Saxagliptin plus vitamin D
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 301

Group type: COMPARATOR
Intervention: Conventional therapy (metformin with or without insulin)
Number of subjects: 301